New Disinfection Technology Expected to Help Combat CRE Threat

Medizone International announces that its patented, peer-reviewed disinfection system -- the vapor-mist technology AsepticSure -- is 'more than capable' of eliminating Carbapenem-resistant Enterobacteriaceae (CRE) from hospital and other healthcare environments.

"Given the growing public, media and health sector interest in the emergence of CRE in hospitals as a highly antibiotic resistant cause of hospital-acquired infections (HAI), we felt that it was important to make public the anticipated effectiveness of AsepticSure with CRE," says Medizone CEO Edwin Marshall.

Michael E. Shannon, MD, MSc, president and director of medical affairs for Medizone, says, "Although we are not permitted to conduct research on extremely dangerous pathogens such as CRE, I can say unequivocally that we have absolutely no difficulty destroying all of its relatives including Klebsiella and E coli which are commonly cited as examples of Enterobacteriaceae. These bacteria are among the easiest for our AsepticSure system to eliminate in that when we achieve a 6 log (99.9999%) kill with MRSA we are usually looking at a 7 log kill for Klebsiella and E coli (99.99999%). I therefore have no doubt that CRE can be completely eradicated from any contaminated space using our AsepticSure system."

AsepticSure has recently been trialed successfully at Belleville General Hospital in Ontario, Canada, and is also the recipient of a WHO award for innovation.

Source: Medizone International